Three Ways Research Could Improve Pancreatic Cancer Treatment
Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
CD123 Targeted Therapies
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A Brighter Future for B-ALL in Adults
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Study Reveals Hidden Immune Defense Mechanism That Could Be Used to Fight Cancer
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Showing 106 - 120 of 1075 results
Previous| 1... 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 ...72 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
